EDGAR Filing Documents for 0001176256-17-000083

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001176256-17-000083

Filing Date

2017-03-31

Accepted

2017-03-31 11:07:16

Documents

Period of Report

2016-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016	nymox20f.htm	20-F	800166
2	SOX SECTION 302 CEO CERTIFICATION	exhibit12-a.htm	EX-12.A	5593
3	SOX SECTION 302 CFO CERTIFICATION	exhibit12-b.htm	EX-12.B	5560
4	SOX SECTION 906 CEO CERTIFICATION	exhibit13-a.htm	EX-13.A	1641
5	SOX SECTION 906 CFO CERTIFICATION	exhibit13-b.htm	EX-13.B	1607
	Complete submission text file	0001176256-17-000083.txt		815613

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 17728677
SIC: 2835 In Vitro & In Vivo Diagnostic Substances